



This is a repository copy of *Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer's disease progression*.

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/160178/>

Version: Published Version

---

**Article:**

De, S. [orcid.org/0000-0003-1675-0773](https://orcid.org/0000-0003-1675-0773), Whiten, D.R., Ruggeri, F.S. et al. (14 more authors) (2019) Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer's disease progression. *Acta Neuropathologica Communications*, 7 (1). 120. ISSN 2051-5960

<https://doi.org/10.1186/s40478-019-0777-4>

---

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:  
<https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

RESEARCH

Open Access



# Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer's disease progression

Suman De<sup>1,10†</sup>, Daniel R. Whiten<sup>1†</sup>, Francesco S. Ruggeri<sup>1,2†</sup>, Craig Hughes<sup>3†</sup>, Margarida Rodrigues<sup>1</sup>, Dimitrios I. Sideris<sup>1</sup>, Christopher G. Taylor<sup>1</sup>, Francesco A. Aprile<sup>1,2</sup>, Serge Muyldermans<sup>4</sup>, Tuomas P. J. Knowles<sup>1,2</sup>, Michele Vendruscolo<sup>1,2</sup>, Clare Bryant<sup>3</sup>, Kaj Blennow<sup>5,6</sup>, Ingmar Skoog<sup>7</sup>, Silke Kern<sup>7</sup>, Henrik Zetterberg<sup>5,6,8,9</sup> and David Klenerman<sup>1,10\*</sup> 

## Abstract

Soluble aggregates of amyloid- $\beta$  (A $\beta$ ) have been associated with neuronal and synaptic loss in Alzheimer's disease (AD). However, despite significant recent progress, the mechanisms by which these aggregated species contribute to disease progression are not fully determined. As the analysis of human cerebrospinal fluid (CSF) provides an accessible window into the molecular changes associated with the disease progression, we characterised soluble aggregates present in CSF samples from individuals with AD, mild cognitive impairment (MCI) and healthy controls using a range of sensitive biophysical methods. We used super-resolution imaging and atomic force microscopy to characterise the size and structure of the aggregates present in CSF and correlate this with their ability to permeabilise lipid membranes and induce an inflammatory response. We found that these aggregates are extremely heterogeneous and exist in a range of sizes, varying both structurally and in their mechanisms of toxicity during the disease progression. A higher proportion of small aggregates of A $\beta$  that can cause membrane permeabilisation are found in MCI CSF; in established AD, a higher proportion of the aggregates were larger and more prone to elicit a pro-inflammatory response in glial cells, while there was no detectable change in aggregate concentration. These results show that large aggregates, some longer than 100 nm, are present in the CSF of AD patients and suggest that different neurotoxic mechanisms are prevalent at different stages of AD.

**Keywords:** Alzheimer's disease, Mild cognitive impairment, Cerebrospinal fluid, Protein aggregation, Structure-function relation, Super-resolution imaging, Disease mechanism

## Introduction

Small soluble aggregates of amyloid- $\beta$  (A $\beta$ ) have been shown to impair hippocampal synaptic plasticity, induce learning deficits and correlate with cognitive impairments both in Alzheimer's disease (AD) mouse models and humans [13, 27, 30, 40]. These soluble aggregates

can exert cellular toxicity via a range of diverse mechanisms, including oxidative stress, disruption of Ca<sup>2+</sup> homeostasis and cellular signalling, mitochondrial alterations, glial activation and inflammation [2, 18]. Many of these processes are the consequence of two fundamental upstream events induced by soluble aggregates: (i) permeabilisation of cell membranes by non-specific binding [6, 15] and (ii) specific interactions with receptors in cell membranes [7, 18]. It is also known that the morphology of protein aggregates can determine the level of their involvement in different biological interactions. Hydrophobic protein aggregates more readily interact with

\* Correspondence: [dk10012@cam.ac.uk](mailto:dk10012@cam.ac.uk)

<sup>†</sup>Suman De, Daniel R. Whiten, Francesco S. Ruggeri and Craig Hughes contributed equally to this work.

<sup>1</sup>Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK

<sup>10</sup>UK Dementia Research Institute at University of Cambridge, Cambridge CB2 0XY, UK

Full list of author information is available at the end of the article



hydrophobic lipid membranes, while the size and shape of the aggregates determine the affinity of binding to receptors [6, 7, 18, 25]. Understanding how the intrinsic heterogeneity in the size, shape and structure of the aggregates present in the human brain influences their mechanism of toxicity and how such heterogeneity changes as AD progresses is crucial in identifying the molecular pathways that lead to neuronal death.

Most of our current knowledge about the origins and morphologies of the toxic soluble species involved in neurodegenerative mechanisms is derived from *in vitro* studies and animal models. These studies have shown the presence of soluble aggregates with large heterogeneity in size (dimer to higher order multimers), shape (small spherical to fibril like) and structure (random coil to  $\beta$ -sheet) [2, 40]. During disease progression, A $\beta$  in the human brain can aggregate into a large number of different forms, consisting of different numbers of peptides, sizes, shapes and structural configurations, with multiple possible post-translational modifications and co-aggregating species. One way to characterise the presence of toxic aggregates at different clinical stages and its implication on disease progression is to study these soluble aggregates present in AD, mild cognitive impairment (MCI) and healthy control cerebrospinal fluid (CSF), since this fluid can reflect at least some of the biochemical changes occurring inside the brain. MCI is a heterogeneous syndrome, which may have many underlying causes [39]. A proportion of MCI patients have AD pathology and are at increased risk of developing AD dementia. MCI can thus be conceptualised as a prodromal state in the AD continuum - a transition between normal cognitive aging and AD [5, 39]. In this study, we used the core AD CSF biomarkers and clinical dementia rating (CDR), which depend on the cognitive ability of individuals (see Methods), to distinguish the MCI cases that had Alzheimer's pathologic changes. These biomarkers used are strongly predictive of the patient having MCI or AD and the agreement is 89–90% [17]. This is also in good agreement with Positron-emission tomography (PET) imaging classification of AD [17]. We have selected MCI cases based on the low level of A $\beta$ 42 (A $\beta$ 42 < 600 ng/L) indicating brain amyloidosis and where the CDR is 0.5. This procedure allowed us to select solely for the MCI cases with brain amyloidosis [21], which will henceforth be referred to as MCI. All the healthy controls are free of MCI and dementia and had a CDR of 0. Therefore, to understand the nature of soluble aggregates present at different stages of AD and how they induce cellular toxicity, we studied CSF samples collected from individuals affected from AD and MCI and compared these with healthy controls.

CSF is continuously produced, recycled and freely exchanged with the interstitial fluid in the brain, making it an ideal reservoir of soluble aggregates that can be reflective of toxic species present in the brain tissue for that disease stage. It has been demonstrated that soluble A $\beta$  is secreted into the CSF, making it an ideal biomarker candidate for AD [4, 24, 39]. The total mass of A $\beta$  oligomers and monomers have been measured in AD CSF using sensitive enzyme-linked immunosorbent assay (ELISA) based methods [4, 22, 38]. In all experiments there is significant overlap in the total mass of A $\beta$  oligomers between control and AD patients, although a small increase in A $\beta$  oligomers mass has been reported for some cohorts [22, 38]. This suggests that structural changes in the A $\beta$  oligomers may be more important in driving disease. However, due to a lack of suitably sensitive methods, the specific detection and quantification of the heterogeneity in morphology of soluble A $\beta$  aggregates present in CSF have not yet been determined. Understanding the changes in these soluble aggregates that occur during disease progression may provide new insights into the disease mechanisms with potential for early diagnosis.

## Materials and methods

### Ad CSF

The CSF used for all the assays was collected by lumbar puncture from patients who sought medical advice because of memory problems. The samples were de-identified and aliquoted into 0.5 mL aliquots in polypropylene cryo tubes following centrifugation at 2,200  $\times$ g in 20°C for 10 min and stored at -80°C pending experimental use. CSF A $\beta$ 1–42, T-tau and P-tau181 were quantified with sandwich ELISAs INNOTEST®  $\beta$ -amyloid<sub>1–42</sub>, hTAU-Ag and Phospho-Tau [181P], respectively (Additional file 1: Table S1). All measurements were performed in clinical laboratory practice by board-certified laboratory technicians using procedures approved by the Swedish Board for Accreditation and Conformity Assessment. Intra-assay coefficients of variation were below 10%. All AD-positive samples had protein levels of A $\beta$ 42 < 600 ng/L, T-tau > 350 ng/L and P-tau181 > 80 ng/L. The study protocol was approved by the regional ethics committee at the University of Gothenburg.

### MCI and control CSF

MCI (6) and control (6) samples were collected from the Gothenburg H70 Birth Cohort Studies in Gothenburg, Sweden [24, 37]. These samples were obtained from the Swedish Population Registry and included both persons living in private households and in residential care and approved by the Regional Ethical Review Board in Gothenburg. As described previously, lumbar punctures to

collect CSF samples were performed in the L3/L4 or L4/L5 inter-space in the morning [3]. The first 10 mL of CSF were collected in a polypropylene tube and immediately transported to the laboratory for centrifugation at 1,800  $\times g$  in 20 °C for 10 min and stored at -80 °C pending experimental use. The supernatant was gently mixed to avoid possible gradient effects, aliquoted in polypropylene tubes and stored at -70 °C [3]. CSF A $\beta$ 42, T-tau and P-tau181 were quantified with sandwich ELISAs INNOTEST®  $\beta$ -amyloid<sub>1-42</sub>, hTAU-Ag and Phospho-Tau [181P], respectively.

As previously published, every 70-year-old in Gothenburg, Sweden, born during 1944 on prespecified birthdates was invited to the examination in 2014–2016, and 1203 participated (response rate 72.2%). Of these, 430 (35.8%) consented to a lumbar puncture [24]. Participants were examined at the Neuropsychiatric memory clinic at Sahlgrenska University Hospital in Gothenburg or at home. Experienced psychiatric research nurses performed the neuropsychiatric examinations, which comprised ratings of psychiatric symptoms and signs, tests of mental functioning, including assessments of episodic memory (short-term, long-term), aphasia, apraxia, agnosia, executive functioning and personality changes. Key informant interviews were performed by psychiatric research nurses as described previously [24, 37]. Examinations included the Mini Mental State Examination and the clinical dementia rating (CDR). Dementia was diagnosed according to the DSM-III-R criteria.

For each participant, the clinical MCI diagnosis was determined in a clinical consensus conference, comprised of a neurologist and psychiatrist, taking into account the participants history and information from informants. CSF biomarker levels of A $\beta$  42, total-tau and Phospho-tau were considered in choosing participants with MCI and underlying preclinical AD pathology. All MCI participants had a clinical dementia rating (CDR) score of 0.5. Healthy controls had to be free of MCI and Dementia and had a CDR of 0. Dementia diagnoses were an exclusion criterion in this study.

All samples were collected in the morning (before lunch) at the highly coordinated memory clinics in south-western Sweden, using clinically implemented CSF sampling protocol that has been detailed in: Blennow et al. [5]. All samples were stored in Gothenburg with only one freeze-thaw cycle.

#### Membrane permeabilisation assay

A detailed protocol and further description of the membrane permeabilisation can be found elsewhere [14]. Briefly, 200 nm mean diameter vesicles composed of 16:0–18:1 PC and 18:1–12:0 biotin PC (100:

1) (Avanti Lipids) were prepared using extrusion and freeze-thaw cycles. Vesicles were filled with 100  $\mu M$  of Cal-520 dye and tethered in the glass surface via biotin-neutravidin linkage. A glass surface was coated using PLL-g-PEG and PLL-g-PEG biotin (10:1) (Susos AG). To measure the background for each set, 9 different images were acquired in the presence of only 30  $\mu L$  Ca<sup>2+</sup> containing buffer, which we denote as blank ( $F_{\text{blank}}$ ). Then a 30  $\mu L$  CSF aliquot was added to the glass coverslip and incubated for 15 min before images of the exact same fields of view were recorded ( $F_{\text{sample}}$ ). Then, 10  $\mu L$  of ionomycin was added to the same coverslip and images of the vesicles were acquired in the same fields of view ( $F_{\text{ionomycin}}$ ). The recorded images were analysed to determine the fluorescence intensity of each vesicle under the three different conditions and the average Ca<sup>2+</sup> influx for each vesicle was calculated using the formula  $(F_{\text{sample}} - F_{\text{blank}}) / (F_{\text{ionomycin}} - F_{\text{blank}}) \times 100\%$ . The stage movements were performed using a bean shell-based program which allows to select fields of view without any user bias. For antibody experiment, CSF and 300 nM antibody were incubated for 15 min and added to the vesicle containing glass coverslip for membrane permeabilisation study.

Imaging of individual vesicles were performed using a home-built total internal reflection fluorescence (TIRF) microscope. For excitation, a 488 nm laser (Toptica) beam was focussed in the back focal plane of the 60 $\times$ , 1.49 NA oil-immersion objective lens (APON60XO TIRF, Olympus, N2709400). Fluorescence emission from the dyes were collected by the same objective and imaged onto an air-cooled EmCCD camera (Photometrics Evolve, EVO-512-M-FW-16-AC-110).

#### Inflammation assay

The BV2 cell line was derived from immortalised murine neonatal microglia and grown in 10% foetal bovine serum and 1% L-Glutamine supplemented Dulbecco's Modified Eagle's (DMEM) medium. The cells were incubated at 37 °C in a humidified atmosphere of 5% CO<sub>2</sub> and 95% air, until the cell density reached approximately  $1.6 \times 10^6$  cell/mL. 200  $\mu L$  of CSF was diluted in 1 mL of DMEM and added to BV2 microglia cells. Every 24 h the supernatant was removed for analysis and replaced by fresh diluted CSF. The TNF- $\alpha$  concentration in the supernatant was quantified using the Duoset® enzyme-linked immunosorbent assay (ELISA) development system (R&D Systems, Abingdon, Oxfordshire, UK). Three wells for each CSF were used to estimate variation in the experiments. For antibody experiment, CSF and antibody were diluted in DMEM buffer and added to the vesicle containing glass coverslip.

### Aptamer-DNA PAINT (AD PAINT) imaging

AD PAINT was performed as described previously<sup>22</sup>. Briefly, glass-slides were cleaned with argon plasma, rinsed with 1% tween-20 and washed with PBS. All buffers were first passed through a 0.02  $\mu\text{m}$  filter (Anotop25, Whatman). The CSF was diluted ten-fold in PBS and added to wells on the coverslip formed by a multiwell chamber coverslip (CultureWell CWCS-50R-1.0). After leaving any aggregates to adhere to the surface for 5 min the CSF was removed, the wells were washed with PBS and then filled with imaging mix (1 nM imaging strand (sequence CCAGATGTAT-CY3B) and 100 nM aptamer-docking strand (sequence GCCTGTGGTGTGGGGCGGGTGC GTTATACAT CTA) in PBS). The wells were then sealed using another clean coverslip. The samples were imaged on a home-built TIRF microscope using a 1.49 N.A., 60x TIRF objective (UPLSAPO, 60X, TIRE, Olympus) mounted on a Ti-E Eclipse microscope (Nikon) fitted with a perfect focus system. The Cy3B was excited at 561 nm (Cobalt Jive, Cobalt) passed through a FF01-561/14-25 excitation filter (Semrock). Fluorescence was separated from the excitation light using a dichroic mirror (Di01-R405/488/561/635, Semrock), passed through a filter (LP02-568RS-25, Semrock) and focussed on the EMCCD camera described above operating in frame transfer mode (electron-multiplying Gain of 11.5 e-/ADU and 250 ADU/photon). To eliminate user bias an automated script (Micro-Manager [12]) was used to collect images in a grid. Five thousand frames were collected with an exposure time of 50 ms. Images were analysed using the Peak Fit ImageJ plugin of the GDSC Single Molecule Light Microscopy package and custom scripts written in Python. The data analysis is described in detail in Whiten et al [43].

### Atomic force microscopy imaging

CSFs are diluted 10x using PBS buffer and image on freshly cleaved mica substrates using AFM. 10  $\mu\text{L}$  diluted CSF samples were deposited on the substrate at room temperature. The samples were incubated for 10 min and followed by rinsing with 1 mL milli Q water. Then the samples were dried using a gentle flow of nitrogen gas. AFM maps were created using a NX10 (Park Systems, South Korea) and JPK nanowizard2 system (JPK Instruments, Germany) operating in non-contact mode. This set-up equipped with a silicon tip with a nominal radius of  $< 10\text{ nm}$ . Scanning Probe Image Processor (SPIP) (Image Metrology, Denmark) software were used for image flattening and single aggregate statistical analysis. The lateral resolution of this technique is determined by the geometry of the AFM tip, although the measurement of the height of individual species is not

significantly affect by the tip geometry. The average level of noise for each image was measured using SPIP software and is well below 0.1 nm. The signal to noise ratio for measuring a single A $\beta$ 42 monomer is close to 10. Thus, the characterisation of cross-sectional height can be performed with high sensitivity and accuracy.

### Confocal imaging of CSF using pentameric formyl thiophene acetic acid (pFTAA)

Single-molecule confocal experiments were performed using the previously-reported method [41]. CSF samples were diluted 1:1 into pentameric formyl thiophene acetic acid (pFTAA) solution (60  $\mu\text{M}$ , PBS) and withdrawn through a single-channel microfluidic device at a flow velocity of 0.56  $\text{cm}\cdot\text{s}^{-1}$ . A 488 nm laser beam (1.5~mW, Spectra Physics Cyan CDRH) was directed to the back aperture of an inverted microscope (Nikon Eclipse TE2000-U). The beam was reflected by a dichroic mirror (51008BS, Chrome) and focussed to a concentric diffraction-limited spot, 10  $\mu\text{m}$  into the solutions in the microfluidic channel through a high numerical aperture oil immersion objective (Apochromat 60X, NA 1.40, Nikon). Fluorescence was collected using the same objective, passing through the same dichroic mirror and imaged onto a 50  $\mu\text{m}$  pinhole (Melles Griot) to remove out-of-focus light. The emission was filtered (535AF45, Omega) and directed to an avalanche photodiode (APD, SPCM-14, Perkin-Elmer Optoelectronics). A custom-programmed field-programmable gate array, FPGA (Colexica), was used to count the signals from the APD and combine these into time-bins which were selected according to the expected residence time of molecules passing through the confocal probe volume. At each time-point data were collected for 10 min (100000-time bins, bin-width 0.2~ms). The experimental output data were collected using an FPGA card and analysed in Python using custom-written code. A threshold of background + 20 was set for all measurements so as to maximise the number of events, whilst removing the noise.

### Production and purification of antibodies

The A $\beta$ -specific nanobody Nb3 was isolated from a llama (*Llama glama*) and amplified from the peripheral blood lymphocytes, as described previously [11]. The concentration was estimated by absorbance spectroscopy at 280 nM using a molecular extinction coefficient, which was calculated based on the sequence of the protein of 21,555  $\text{M}^{-1}\text{cm}^{-1}$ . Nb3 binds to the epitope 17-28 of A $\beta$  with a measured  $K_d$  for the monomer of 13 nM [32].

Rationally designed antibodies to A $\beta$ 42 were generated as previously described [1, 10]. These antibodies are designed to preferentially bind the target epitope when the protein is in the aggregated rather than in the monomeric conformation. Briefly, complementary peptides were selected using the cascade method to target linear epitopes within A $\beta$ 42 that scan its entire sequence. These complementary peptides were then grafted into the complementarity determining region 3 of an antibody scaffold by means of a mutagenic polymerase chain reaction with phosphorylated oligonucleotides. The DesAb variants were overexpressed and purified using pRSET-B vector in *E. coli* BL21 (DE3) Gold Strain. Overnight Express Instant TB Medium (Merck Millipore) supplemented with 100  $\mu$ g/ml ampicillin were used as a medium for cell growing. Then it was harvested by centrifugation; resuspended in phosphate-buffered saline (PBS), then one tablet of EDTA-Free Complete Protease Inhibitor Cocktail (Roche) was added to 500 mL of cell growth media. Then cells are lysed by sonication and debris was removed by centrifugation at 15,000 rpm (JA-20 rotor, Beckman Coulter). The cleaned lysate was loaded onto a Ni<sup>2+</sup> – NTA Superflow column (Qiagen) using PBS with 10 mM imidazole. Then His-tagged DesAbs were eluted with PBS containing 200 mM imidazole and lastly the imidazole was then removed using size exclusion chromatography. Protein concentration was determined by absorbance measurement at 280 nm using theoretical extinction coefficients and calculated with ExPASy ProtParam. Previous experiments have confirmed that the rationally designed antibodies bind to their target epitopes. The affinity for monomeric A $\beta$  is in the range 200 to 900 nM, while the affinity for A $\beta$  aggregates is in the range 1–10 nM [1, 10].

### Statistical tests

To assess the statistical significance of the difference among AD, MCI and control CSF for membrane permeability assay, we performed a two-sample t-test (unpaired) (Fig. 1b) using origin 9.0. We also used the same two-sample t-test (unpaired) assay to check if the antibodies significantly inhibit CSF-induced membrane permeabilisation ( $n = 3$ ) (Fig. 2b. and Additional file 1: Figure S2). To determine the statistical significance of the results on the inflammatory response induced by AD, control and MCI CSF samples (Fig. 1d) and on the antibody-induced inhibition of the toxicity of AD CSF samples we also performed two-sample t-test (unpaired) at 96 h ( $n = 3$ ) (Fig. 2a). The number of aggregates present in the CSF samples was tested using a one-way ANOVA with Tukey's Multiple Comparison post-test (Fig. 3b and Additional file 1: Figure S1). Significance in the


differences of the size distributions of the aggregates were evaluated using the Kolmogorov-Smirnov test (Fig. 3f, g).

## Results and discussions

### Soluble aggregates present in AD and MCI CSF induce toxicity by distinct mechanisms

We used CSF from individuals diagnosed with MCI, AD as well as healthy controls to perform a series of proof of concept experiments on a small set of clinical samples of CSF to explore if our assays could detect differences between the aggregates present in CSF at different stages of AD. We first set out to analyse the toxicity of the soluble aggregates in CSF by measuring their ability to permeabilise lipid membranes and induce an inflammatory response. As the non-specific binding of protein aggregates to lipid membranes is driven in particular by hydrophobic interactions, aggregates with more hydrophobic patches show increased toxicity via disruption and permeabilisation of the lipid membrane. To quantitatively measure how the soluble aggregates act in this manner, we used a recently developed biophysical assay, which has shown that physiological concentrations of soluble aggregates of A $\beta$  can destabilise lipid membranes [9, 14]. For this assay, we immobilised thousands of single POPC vesicles (mean diameter - 200 nm) containing the Ca<sup>2+</sup>-specific dye, Cal-520, onto PEGylated glass cover slides via biotin-neutravidin linkage. When CSF samples are added, soluble aggregates present permeabilise the membrane of lipid vesicles and Ca<sup>2+</sup> from the surrounding solution enter individual vesicles causing a change in the fluorescence intensity of the dye (Fig. 1a). The change in fluorescence intensity in these nano-sized vesicles is proportional to the number of ions that entered and can be quantified using TIRF microscopy [14, 20]. Using this sensitive method capable of detecting entry of a single Ca<sup>2+</sup> ion, we found that aliquots of MCI CSF cause greater membrane permeabilisation compared to the AD and control CSF (Fig. 1b). By contrast, we found no significant difference in membrane permeation induced by AD and control CSF, in agreement with a previously reported study [11].


We instead observed the opposite trend in the CSF-induced pro-inflammatory response in glial cells (Fig. 1c). Physiological concentrations of protein aggregates can interact with specific membrane receptors in microglial cells and induce a proinflammatory response [19]. This response can be quantified by measuring secreted tumour necrosis factor alpha (TNF- $\alpha$ ), one of the pro-inflammatory cytokines that is produced, using an ELISA assay. To sensitively determine if CSF samples can induce a



proinflammatory response, we added them to BV2 microglia cells and incubated for 5 days. These cells develop a sensitised response to the aggregates over time, leading to a detectable increase in TNF- $\alpha$  secretion, as we observed previously with synthetic aggregates of alpha synuclein [19]. Every 24 h, we took the supernatant above the cells and measured the TNF- $\alpha$  concentration. We found that over time the CSF aliquots can activate an innate immune response leading to the production of significant amounts of TNF- $\alpha$ . We observed that AD CSF samples induced a stronger inflammatory response than the MCI and control CSF samples (Fig. 1d). This inflammatory response induced by AD CSF was significantly blocked by *Rhodobacter sphaeroides* lipid A (RSLA), a known Toll-like receptor (TLR)-4 antagonist [33] and TAK-242, a small-molecule inhibitor that binds selectively and inhibits signalling of TLR-4 [23] showing that signalling is mediated by TLR-4 (Additional file 1: Figure S1).

### Soluble amyloid- $\beta$ aggregates present in AD and MCI CSF are structurally distinct


We explored the feasibility of performing immunodepletions in CSF, using antibodies on beads, but found that the non-specific control antibody also reduced the number of detectable aggregates and the amount of membrane permeabilization to the same extent as the specific antibody. This was due to the non-specific binding of the low concentration of aggregates in the CSF to the hydrophobic beads. Therefore, to gain insight into the composition of the soluble aggregates responsible for the observed membrane permeabilisation we used several antibodies raised against A $\beta$  to determine whether they could block the CSF-induced toxicity. A relatively high dynamic range is required to perform these experiments so they were therefore performed on the three MCI and AD CSF samples that showed the highest level of membrane permeabilization. To this end, we employed a series of A $\beta$ -specific antibodies which were previously shown to counteract the toxicity induced by soluble



**Fig. 2** The toxic soluble aggregates present in MCI and AD CSF contain A $\beta$ . A significant inhibition of the membrane permeabilisation of lipid membranes by (a) AD and (b) MCI CSF samples is caused by a nanobody Nb3 (300 nM) designed to bind to A $\beta$ , indicating that some of the aggregates present in MCI and AD CSF contain A $\beta$ . Nb3 recognises amino acids 17–28 of the A $\beta$  sequence and shown to inhibit toxicity induced by protein aggregates of A $\beta$  cerebrospinal fluid samples from AD patient (c) Both N-terminally and C-terminally targeting antibodies significantly inhibit MCI CSF-induced membrane permeabilisation. However, we do not find any significant difference between their activities. Error bars are the standard deviation among data points. Two sample unpaired t-tests were performed to compare the data sets ( $n = 3$ ). d A N-terminal binding antibody (binding the region of residues 3–9 of A $\beta$ 42) is more potent at reducing the aggregate-induced inflammatory response than a C-terminal designed antibody (binding the region of residues 36–42 of A $\beta$ 42);  $P$  values are calculated using a two sample t-test to compare the inhibition by an N-terminally binding antibody and a C-terminally antibody at 96 h ( $n = 3$ ). Error bars are the standard deviation among data points

aggregates of A $\beta$  both in vitro and in AD CSF. Firstly we used an antibody Nb3 which recognises the NAC region (aa17–24) of the A $\beta$  sequence, and found it was able to significantly reduce the aggregate-induced membrane permeabilisation for both AD and MCI (Fig. 2a, b). It was used at a concentration of 300 nM, 20-fold higher than its  $K_d$  (~13 nM) [32]. We also used two different aggregate specific designed antibodies which were shown to target regions near the N- and C- termini (aa3–9 and 36–42, respectively) of the A $\beta$  peptide to confirm our

findings [25, 30]. We found that both the antibodies recognising the N-terminus and C-termini were both effective at reducing lipid membrane permeation (Fig. 2c). These results indicate that at least a portion of the toxic aggregates present in MCI and AD CSF are composed of A $\beta$ . In contrast, a non-specific control antibody did not reduce membrane permeabilization (Additional file 1: Figure S2). We also found that the antibody that targets the N-terminus of A $\beta$ , but not the antibody that targets the C-terminus, efficiently inhibits an AD CSF-induced



**Fig. 3** Super-resolution imaging of aggregates present in CSF using AD-PAINT. **a** Schematic of AD-PAINT. Dye-labelled DNA imaging strands transiently bind to their complementary target sequence (docking strand), which is attached to a protein aggregate via aptamer. This transient binding between imaging and docking strand is detected. Repeated cycles of binding and unbinding allows a super-resolved image of individual protein aggregate present in CSF to be determined. The right image shows examples of super-resolved image of protein aggregates from CSF. Three individual protein aggregates present in CSF are enlarged. The lengths of the aggregates shown are: (i) 47 nm, (ii) 34 nm and (iii) 118 nm. **b** Number of aggregates present in control, MCI and AD CSF samples. Each point represents one field of view. **c** Cumulative frequency histograms of the size distributions of all aggregates measured. **d, e** Differences between normalised histograms of the size distributions of the indicated CSF samples. **f, g** Differences between the cumulative frequency histograms of the size distributions of the indicated CSF samples. The dotted line indicates 99% confidence using the Kolmogorov-Smirnov statistical test. (n = 6 AD, 6 MCI, 6 control CSF)

inflammatory response (Fig. 2d). The differential effects of N-terminal and C-terminal antibodies provide information not only on the composition but also on the structure of the soluble aggregates present in AD CSF. Mature fibrillar aggregates have a hydrophobic C-terminus which is inaccessible to C-terminal antibodies, while the N-terminus residues of aggregates are exposed [16, 28, 31]. These results suggest that the aggregates present in the CSF that are responsible for inducing membrane permeation are structurally distinct from those that induce an inflammatory response.

#### **Single aggregate super-resolution imaging shows the differing size distributions of soluble aggregates present in AD and MCI CSF**

To examine the size and morphology of these soluble aggregates, we employed a newly developed super-resolution technique, aptamer DNA PAINT (ADPAINT) (Fig. 3a) [43]. The small size of the aptamer in combination with its remarkable specificity and affinity allows us to resolve aggregated structures of A $\beta$  with a precision of approximately 20 nm. We have previously demonstrated the utility of this imaging technique by accurately identifying and nanoscopically characterising the shapes and sizes of the species formed during an aggregation reaction and in iPSC neurons [43]. Using this technique, we analysed the average number of aggregates present in the CSF samples and measured the size of individual aggregates (Fig. 3b,c), which ranged from 20 nm, limited by our resolution, to 300 nm. We did not find any significant difference in the total number of aggregated species present among MCI, AD and control CSF samples (6 each), a result that we confirmed using the amyloid-specific dye PFTAA (Additional file 1: Figure S3).


To examine the aggregate morphologies, we plotted the relative differences between normalised (Fig. 3d,e) and cumulative (Fig. 3f,g) histograms of the size distributions of aggregates present in control vs MCI and AD CSF samples. In the plots of relative differences negative values indicate that more aggregates of that size are present in the disease CSF, whereas positive values indicate more aggregates of that size are present in control CSF. Similarly, a negative slope indicates more aggregates of that size are present in disease CSF when looking at the cumulative differences. We found that, with 99% confidence, the number of small aggregates (< 50 nm) present in MCI CSF was higher than that found in control CSF (Fig. 3d,f). This result suggests that a relatively larger number of small aggregates might be accountable for enhanced membrane permeabilisation induced by MCI CSF. This finding agrees with previously reported studies that small sized A $\beta$  aggregates are more hydrophobic and have greater tendencies to

interact, permeabilise and cross the plasma membrane [6, 25]. In contrast, a ten-fold larger change was observed in the size distribution of AD CSF compared to control CSF, with a larger number of longer, mature aggregates (~ 40 to 200 nm) (Fig. 3e,g). Together, these results, in combination with the AD CSF-induced inflammation inhibition by an N-terminus antibody (Fig. 2a) suggest that relatively longer aggregates present in AD CSF might be responsible for the increased inflammatory response. Additionally, these data are also in agreement with previous reports on synthetic A $\beta$  aggregates, which cannot undergo post-translational modifications. It was found that A $\beta$  aggregates greater than 100 nm formed in artificial CSF can trigger an inflammatory response in microglial cells that can be blocked by an A $\beta$  N-terminal region recognising antibody [8, 31, 42]. We also recently reported results that small aggregates of A $\beta$ 42 which form during the early stages of aggregation are more potent at membrane permeabilisation, whereas protofilament aggregates of similar length to the aggregates detected in CSF with height of 0.4–1 nm, which form at later stages of aggregation, are more effective at inducing inflammatory response in murine glial cells via TLR4 receptor [10]. Thus, the data on synthetic A $\beta$  aggregates also supports the idea that longer A $\beta$  aggregates in AD CSF cause neuroinflammation.

The increase in the relative proportion of large aggregates means that there is also a small increase in the total mass of A $\beta$  present in AD CSF, as also previously detected by ELISAs. However, ELISA cannot measure the mass and aggregate number independently. This may explain why it is difficult to detect a clear difference between control and AD CSF since both factors contribute to the total aggregate mass detected in a given sample. This also suggests that the observed reduction in A $\beta$  monomer concentration in AD CSF is partially due to this increased mass of aggregates, although this cannot account for the entire reduction and presumably there is also significant deposition of aggregates in the brain.

#### **Structural characterisation of soluble aggregates presents in CSF using high resolution atomic force microscopy (AFM) at the single aggregate level**

To measure the heterogeneity and three-dimensional morphological properties of the protein aggregates present in the CSF samples, we utilised a phase controlled AFM technique to resolve the structures of individual protein aggregates at Angstrom resolution [35, 36] (Fig. 4). This allowed us to determine the heights of the individual species present in the CSF. For these experiments the samples of CSF were dried directly onto a mica surface. The control CSF sample showed the uniform presence of abundant spherical species, whereas both the MCI and AD samples



**Fig. 4** Characterization of the protein aggregates present in CSF samples at single aggregate level using AFM. **a-c** Representative AFM images of the aggregates present at different CSF samples with **(d-j)** a magnified example of the species present. **j, k** Statistical analysis of the cross-sectional length and heights of individual aggregates present in CSF samples; the length of the individual aggregates are shown as a box chart

showed the co-existence of spherical species and elongated aggregates (Fig. 4). We then performed a statistical analysis of their cross-sectional length and heights of individual aggregates [35]. The MCI CSF sample showed a relatively uniform population of elongated aggregates with a cross-sectional height ranging between 0.3–1 nm (Fig. 4b) and length 50–100 nm (Fig. 4c), larger than the typical length of species in the control sample ( $p < 0.001$ ). The AD CSF samples showed the coexistence of highly heterogeneous elongated aggregates. These species belonged roughly to two populations of height, the first with cross sectional height ranging between 0.3–1 nm which is similar to the species present in MCI CSF aggregates, often referred to as protofilaments, and the second with cross-sectional height between 1 and 3 nm, often referred to as protofibrils. A larger cross-sectional aggregate height has been associated in vitro to an increased content of intermolecular  $\beta$ -sheet and maturity of amyloid structure [36]. The AD elongated aggregates are significantly longer than the MCI CSF sample ( $p < 0.001$ ), ranging in length between 50 and 400 nm. This data is highly consistent with the super-resolution imaging data suggesting that the same species are being detected in both experiments. These data, in conjunction with the AD PAINT data, confirm that the protein aggregates present in AD CSF differ in structure from the aggregates present in MCI and control CSF. We cannot formally conclude that these species are  $A\beta$  aggregates since the AFM measurement is composition insensitive. However, we have shown that a higher proportion of longer aggregates are present in AD CSF and that this correlates with increased inflammation. Overall these findings suggest that long  $A\beta$  protofibrils cause the increased inflammation detected in AD CSF. It has also been shown that the protofibrillar aggregate of amyloid beta can cause the inflammation in murine BV2 cells [10]. Interestingly and in support of this conclusion, there is a crystal structure of TLR3, which is in the same family as TLR4, bound to an RNA dimer which is about 2 nm in diameter [29]. TLR3 signalling occurs when the RNA dimer is longer than 15 nm [26]. Since the long AD protofibrillar aggregates, have a cross-sectional height of round 2 nm, this provides a plausible explanation of how they cause TLR4 signalling in AD CSF.

## Conclusions

In conclusion, we have reported that there is a higher proportion of small aggregates that can cause increased membrane permeabilisation present in MCI CSF than in AD and control CSF, while in AD CSF there is an increased number of larger and longer aggregates, corresponding

with enhanced neuroinflammation. These larger aggregates appear to be protofibrillar in nature, with distinct structural features from those of the smaller aggregates and appear to be the species that initiates cytokine production via TLR4 signalling.

It has to be noted that our study has been performed on a small number of samples and in future work it would be of interest to see if we observe the same changes in aggregate size distributions in bigger cohorts. If replicated then following the changes in aggregate size distribution provides a method to follow disease progression that does not require the measurement of the absolute number of aggregate species, with the proportion of larger aggregates increasing. Our results indicate that as the disease progresses there are changes in the aggregate size distribution in CSF but not in the total number of species. It has been reported that there is a three-fold increase in  $A\beta$  aggregates deposited in the brain during the development of AD [34]. Taken together this suggests that there is a change in both aggregate number and size distribution in the brain during the development of AD, but only the change in aggregate size distribution is detectable in the CSF sampled in a lumbar puncture. This change in aggregate size distribution may be important in the disease mechanism since it corresponds with a change in aggregate structure and changes the dominant mechanism of aggregate-induced cellular toxicity. This in turn suggests that a combination of therapeutic agents targeting aggregated species with varying size and morphology, rather than a single agent targeting a single structure of one toxic form of  $A\beta$  may be needed to develop effective treatments for AD. Lastly, our data shows that sensitive biophysical methods are now capable of characterising the aggregates present in human CSF at new levels of detail, providing an opportunity to determine what changes in aggregate size and structure correlate with different stages of disease and new information about the species that initiate and drive the development of AD.

## Additional file

**Additional file 1: Table S1.** Characterisation of the CSF samples used in this study. **Figure S1** Toll like receptor 4 (TLR4) antagonists block AD CSF-induced aggregate induced inflammation. **Figure S2** a portion of the toxic aggregates present in MCI and AD CSF are composed of  $A\beta$  To understand the composition of toxic aggregate present in human CSF, we employed a series of  $A\beta$ -specific antibody which are known to counteract the toxicity induced by soluble aggregates of  $A\beta$ . **Figure S3** Detection of aggregates present in control, MCI and AD CSF using pFTAA. (DOCX 197 kb)

## Abbreviation

AD: Alzheimer's disease; AFM: Atomic force microscopy; CDR: Clinical dementia rating; CSF: Cerebrospinal fluid; ELISA: Enzyme-linked immunosorbent assay; MCI: Mild cognitive impairment; PET: Amyloid- $\beta$  ( $A\beta$ ) Positron-emission tomography; pFTAA: Pentameric formyl thiophene acetic

acid; RSLA: Rhodobacter sphaeroides lipid A; TIRF: Total internal reflection fluorescence; TLR: Toll-like receptor; TNF- $\alpha$ : Tumour necrosis factor alpha

#### Acknowledgements

DRW is supported by a Herchel Smith Fellowship. CGT is supported by the European Research Council (669237), KB is supported by the Torsten Söderberg Foundation, Sweden. FAA is supported by a Senior Research Fellowship award from the Alzheimer's Society, UK. SK was supported by the Swedish state under the agreement between the Swedish Government and the county councils, the ALF-agreement (ALFGBG-813921, ALFGBG-65930, ALF-GBG-716681) and the Swedish Alzheimer Foundation. The Gothenburg H70 Birth Cohort Study was supported by grants from the Swedish Research Council (grants no 2015-02830, 2013-8717), Swedish Research Council for Health, Working Life and Wellfare (grants no 2013-1202, 2013-2300, 2013-2496), Alzheimerfonden, Hjärnfonden and the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (grants no ALF 716681). HZ is a Wallenberg Academy Fellow supported by grants from the Swedish Research Council (grants no 2018-02532), the European Research Council (grants no 681712) and Swedish State Support for Clinical Research (ALFGBG-720931). DK was supported by the Royal Society, the European Research Council with an ERC Advanced Grant (grants no 669237) and ARUK.

#### Authors' contribution

SD, DRW, CH, FSR, MR, DIS and CGT performed experiments and analysed the data. KB, IS, SK and HZ collected, analysed and provided the CSF samples. SM provided Nb3 antibody and FAA and MV provided the rationally designed antibody. SD, DRW, MV and DK wrote the manuscript. All authors discussed the results and contributed to the manuscript writing. SD and DK conceived the idea and designed the study. DK supervised the project. All authors read and approved the final manuscript.

#### Availability of data and materials

All data and codes are available from the authors upon reasonable request.

#### Competing interests

CEB is a member of the GSK Immunology Catalyst, serves on the scientific advisory board of Nodthera, is a consultant for Syncona and a co-founder of Polypharmakos. KB has served as a consultant or at advisory boards for Alecator, Alzheon, CogRx, Biogen, Lilly, Novartis and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. IS has served as a consultant for Takeda. HZ has served at scientific advisory boards for Roche Diagnostics, Wave, Samumed and CogRx and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg, all unrelated to the work presented in this paper. All the other authors declare no competing interests.

#### Author details

<sup>1</sup>Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK. <sup>2</sup>Centre for Misfolding Diseases, University of Cambridge, Cambridge CB2 1EW, UK. <sup>3</sup>Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, UK. <sup>4</sup>Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium. <sup>5</sup>Clinical Neurochemistry Laboratory, Unit of Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Göteborg, Sweden. <sup>6</sup>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden. <sup>7</sup>Neuropsychiatric Epidemiology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Göteborg, Sweden. <sup>8</sup>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, Queen Square, London, UK. <sup>9</sup>UK Dementia Research Institute at University College London, London, UK. <sup>10</sup>UK Dementia Research Institute at University of Cambridge, Cambridge CB2 0XY, UK.

Received: 16 July 2019 Accepted: 18 July 2019

Published online: 26 July 2019

#### References

- Aprile FA, Sormanni P, Perni M, Arosio P, Linse S, Knowles TPJ et al (2017) Selective targeting of primary and secondary nucleation

- pathways in A $\beta$ 42 aggregation using a rational antibody scanning method. *Sci Adv* 3:e1700488 Available from: <https://advances.sciencemag.org/content/3/6/e1700488>
- Benilova I, Karran E, De Strooper B (2012) The toxic A $\beta$  oligomer and Alzheimer's disease: an emperor in need of clothes. *Nat Neurosci* 15: 349–357. <https://doi.org/10.1038/nn.3028>
- Bjerke M, Kern S, Blennow K, Zetterberg H, Waern M, Börjesson-Hanson A et al (2016) Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years. *J Alzheimer's Dis* 49: 733–741 Available from: <https://content.iospress.com/articles/journal-of-alzheimers-disease/jad150525>
- Blennow K (2004) Cerebrospinal fluid protein biomarkers for Alzheimer's disease. *NeuroRX* 1:213–225. <https://doi.org/10.1602/neuroRx.1.2.213>
- Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. *Nat rev Neurol* 6: 131. <https://doi.org/10.1038/nrneuro.2010.4>
- Campioni S, Mannini B, Zampagni M, Pensalfini A, Parrini C, Evangelisti E et al (2010) A causative link between the structure of aberrant protein oligomers and their toxicity. *Nat Chem Biol* 6:140–147. <https://doi.org/10.1038/nchembio.283>
- Chakrabarty P, Li A, Ladd TB, Strickland MR, Koller EJ, Burgess JD et al (2018) TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer's disease. *J Exp Med* 215:2247–2264 Available from: <http://jem.rupress.org/content/215/9/2247>
- Colvin BA, Rogers VA, Kulas JA, Ridgway EA, Amtashar FS, Combs CK et al (2017) The conformational epitope for a new A $\beta$ 42 protofibril-selective antibody partially overlaps with the peptide N-terminal region. *J Neurochem* 143:736–749. <https://doi.org/10.1111/jnc.14211>
- De S, Klenerman D (2019) Imaging individual protein aggregates to follow aggregation and determine the role of aggregates in neurodegenerative disease. *Biochim Biophys Acta Proteins Proteomics* Available from: <https://www.sciencedirect.com/science/article/pii/S1570963919300044>
- De S, Wirthensohn DC, Flagmeier P, Hughes C, Aprile FA, Ruggeri FS et al (2019) Different soluble aggregates of A $\beta$ 42 can give rise to cellular toxicity through different mechanisms. *Nat Commun* 10:1541. <https://doi.org/10.1038/s41467-019-09477-3>
- Dreus A, De S, Flagmeier P, Wirthensohn D, Chen W-H, Whiten D et al (2017) Inhibiting the Ca<sup>2+</sup> influx induced by human CSF. *Cell Rep* 21:3310–3316 Available from: [http://www.cell.com/cell-reports/fulltext/S2211-1247\(17\)31709-6](http://www.cell.com/cell-reports/fulltext/S2211-1247(17)31709-6)
- Edelstein AD, Tsuchida MA, Amodaj N, Pinkard H, Vale RD, Stuurman N (2014) Advanced methods of microscope control using µManager software. *J Biol Methods* 1:1–10 Available from: <http://www.jbmethods.org/jbm/article/view/36/29>
- Fidani L, Goulas A, Mirtsou V, Petersen RC, Tangalos E, Crook R et al (2002) Interleukin-1A polymorphism is not associated with late onset Alzheimer's disease. *Neurosci Lett* 323. [https://doi.org/10.1016/S0304-3940\(02\)00114-3](https://doi.org/10.1016/S0304-3940(02)00114-3)
- Flagmeier P, De S, Wirthensohn DC, Lee SF, Vincke C, Muyldermans S et al (2017) Ultrasensitive Measurement of Ca<sup>2+</sup> Influx into Lipid Vesicles Induced by Protein Aggregates. *Angew Chemie - Int Ed* 56: 7750–7754 Available from: <http://onlinelibrary.wiley.com/doi/10.1002/anie.201700966/abstract>
- Fusco G, Chen SW, Williamson PTF, Cascella R, Perni M, Jarvis JA et al (2017) Structural basis of membrane disruption and cellular toxicity by  $\alpha$ -synuclein oligomers. *Science* 358:1440–1443 Available from: <http://science.sciencemag.org/content/358/6369/1440.abstract>
- Gremer L, Schölzel D, Schenk C, Reinartz E, Labahn J, Ravelli RBG et al (2017) Fibril structure of amyloid- $\beta$ (1–42) by cryoelectron microscopy. *Science* 358: 116–119 Available from: <https://science.sciencemag.org/content/358/6359/116>
- Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, et al CSF biomarkers of Alzheimer's disease concord with amyloid- $\beta$ - $\tau$ ; PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. *Alzheimer's Dement J Alzheimer's Assoc* 2018; 14:1470–1481. doi: <https://doi.org/10.1016/j.jalz.2018.01.010>
- Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL et al (2015) Neuroinflammation in Alzheimer's disease. *Lancet Neurol* 14: 388–405 Available from [https://www.thelancet.com/journals/lanneur/article/PIIS1474-4422\(15\)70016-5/fulltext](https://www.thelancet.com/journals/lanneur/article/PIIS1474-4422(15)70016-5/fulltext)

19. Hughes CD, Choi ML, Ryten M, Hopkins L, Drews A, Botia JA et al (2019) Picomolar concentrations of oligomeric alpha-synuclein sensitizes TLR4 to play an initiating role in Parkinson's disease pathogenesis. *Acta Neuropathol* 137:103–120. <https://doi.org/10.1007/s00401-018-1907-y>
20. Ilijina M, Dear AJ, Garcia GA, De S, Tosatto L, Flagmeier P et al (2018) Quantifying co-oligomer formation by  $\alpha$ -Synuclein. *ACS Nano* 12:10855–10866. <https://doi.org/10.1021/acsnano.8b03575>
21. Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer's disease. *Alzheimer's Dement* 14:535–562 Available from: <http://www.sciencedirect.com/science/article/pii/S1552526018300724>
22. Jekel K, Damian M, Wattmo C, Hausner L, Bullock R, Connelly PJ et al (2015) Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review. *Alzheimers res Ther* 7:17. <https://doi.org/10.1186/s13195-015-0099-0>
23. Kawamoto T, Ii M, Kitazaki T, Iizawa Y, Kimura H (2008) TAK-242 selectively vresses Toll-like receptor 4-signaling mediated by the intracellular domain. *Eur J Pharmacol* 584:40–48 Available from: <http://www.sciencedirect.com/science/article/pii/S0014299908000952>
24. Kern S, Zetterberg H, Kern J, Zettergren A, Waern M, Höglund K et al (2018) Prevalence of preclinical Alzheimer disease. *Neurology* 90:e1682 LP–e16e1691 Available from: <http://n.neurology.org/content/90/19/e1682.abstract>
25. Kremer JJ, Pallitto MM, Sklansky DJ, Murphy RM (2000) Correlation of  $\beta$ -amyloid aggregate size and hydrophobicity with decreased bilayer fluidity of model membranes. *Biochemistry* 39:10309–10318. <https://doi.org/10.1021/bi0001980>
26. Leonard JN, Ghirlando R, Askins J, Bell JK, Margulies DH, Davies DR et al (2008) The TLR3 signaling complex forms by cooperative receptor dimerization. *Proc Natl Acad Sci* 105:258 LP–258263 Available from: <http://www.pnas.org/content/105/1/258.abstract>
27. Lesné S, Koh MT, Kotilinek L, Kaye R, Glabe CG, Yang A et al (2006) A specific amyloid-beta protein assembly in the brain impairs memory. *Nature* 440:352–357 Available from: <https://www.nature.com/articles/nature04533>
28. Li S, Jin M, Liu L, Dang Y, Ostaszewski BL, Selkoe DJ (2018) Decoding the synaptic dysfunction of bioactive human AD brain soluble A $\beta$  to inspire novel therapeutic avenues for Alzheimer's disease. *Acta Neuropathol Commun* 6:121. <https://doi.org/10.1186/s40478-018-0626-x>
29. Liu L, Botos I, Wang Y, Leonard JN, Shiloach J, Segal DM et al (2008) Structural Basis of Toll-Like Receptor 3 Signaling with Double-Stranded RNA. *Science* 320:379 LP–379381 Available from: <http://science.sciencemag.org/content/320/5874/379.abstract>
30. Mc Donald JM, Savva GM, Brayne C, Welzel AT, Forster G, Shankar GM et al (2010) The presence of sodium dodecyl sulphate-stable A $\beta$  dimers is strongly associated with Alzheimer-type dementia. *Brain* 133:1328–1341. <https://doi.org/10.1093/brain/awq065>
31. Paranjape GS, Terrill SE, Gouwens LK, Ruck BM, Nichols MR (2013) Amyloid- $\beta$  (1–42) Protofibrils formed in modified artificial cerebrospinal fluid bind and activate microglia. *J Neuroimmune Pharmacol* 8:312–322. <https://doi.org/10.1007/s11481-012-9424-6>
32. Paraschiv G, Vincke C, Czaplowska P, Manea M, Muyldermans S, Przybylski M (2013) Epitope structure and binding affinity of single chain llama anti- $\beta$ -amyloid antibodies revealed by proteolytic excision affinity-mass spectrometry. *J Mol Recognit* 26:1–9 Available from <https://onlinelibrary.wiley.com/doi/abs/10.1002/jmr.2210>
33. Rallabhandi P, Phillips RL, Boukhvalova MS, Pletneva LM, Shirey KA, Giannini TL et al (2012) Respiratory Syncytial Virus Fusion Protein-Induced Toll-Like Receptor 4 (TLR4) Signaling Is Inhibited by the TLR4 Antagonists Rhodobacter sphaeroides Lipopolysaccharide and Eritoran (E5564) and Requires Direct Interaction with MD-2. *Pier G, editor. MBio* 3:e00218–e00212 Available from: <http://mbio.asm.org/content/3/4/e00218-12.abstract>
34. Roberts BR, Lind M, Wagen AZ, Rembach A, Frugier T, Li Q-X et al (2017) Biochemically-defined pools of amyloid- $\beta$  in sporadic Alzheimer's disease: correlation with amyloid PET. *Brain* 140:1486–1498 Available from: <https://doi.org/10.1093/brain/awx057>
35. Ruggeri FS, Benedetti F, Knowles TPJ, Lashuel HA, Sekatskii S, Dietler G (2018) Identification and nanomechanical characterization of the fundamental single-strand protofilaments of amyloid  $\alpha$ -synuclein fibrils. *Proc Natl Acad Sci* 115:7230 LP–7237235 Available from: <http://www.pnas.org/content/115/28/7230.abstract>
36. Ruggeri FS, Longo G, Faggiano S, Lipiec E, Pastore A, Dietler G (2015) Infrared nanospectroscopy characterization of oligomeric and fibrillar aggregates during amyloid formation. *Nat Commun* 6:7831 Available from: <https://doi.org/10.1038/ncomms8831>
37. Rydberg Sterner T, Ahlner F, Blennow K, Dahlin-Ivanoff S, Falk H, Havstam Johansson L et al (2018) The Gothenburg H70 Birth cohort study 2014–16: design, methods and study population. *Eur J Epidemiol*. <https://doi.org/10.1007/s10654-018-0459-8>
38. Savage MJ, Kalinina J, Wolfe A, Tugusheva K, Korn R, Cash-Mason T et al (2014) A sensitive A $\beta$  oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid. *J Neurosci* 34:2884–2897 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24553930>
39. Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S et al (2016) Alzheimer's disease. *Lancet* 388:505–517. Available from [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(15\)01124-1/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01124-1/fulltext)
40. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I et al (2008) Amyloid- $\beta$  protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. *Nat Med* 14:837–842 Available from <https://www.nature.com/articles/nm1782>
41. Taylor CG, Meisl G, Horrocks MH, Zetterberg H, Knowles TPJ, Klenerman D (2018) Extrinsic amyloid-binding dyes for detection of individual protein aggregates in solution. *Anal Chem* 90:10385–10393. <https://doi.org/10.1021/acs.analchem.8b02226>
42. Terrill-Usery SE, Colvin BA, Davenport RE, Nichols MR (2016) A $\beta$ 40 has a subtle effect on A $\beta$ 42 protofibril formation, but to a lesser degree than A $\beta$ 42 concentration, in A $\beta$ 42/A $\beta$ 40 mixtures. *Arch Biochem Biophys* 597:1–11 Available from: <http://www.sciencedirect.com/science/article/pii/S0003986116300686>
43. Whiten DR, Zuo Y, Calo L, Choi M-L, De S, Flagmeier P et al (2018) Nanoscopic characterisation of individual endogenous protein aggregates in human neuronal cells. *ChemBioChem* 19:2033–2038. <https://doi.org/10.1002/cbic.201800209>

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

